Chinook Therapeutics is now a Novartis Company! On August 11, 2023, Novartis completed its acquisition of Chinook. Follow Novartis to stay updated on atrasentan, zigakibart (BION-1301) and the rest of the Chinook pipeline.
Chinook Therapeutics, a Novartis Company
Biotechnology Research
Seattle, WA 12,531 followers
Changing the Course of Kidney Care
About us
Chinook Therapeutics is now a Novartis Company! On August 11, 2023, Novartis completed its acquisition of Chinook. Follow the Novartis channel or visit www.novartis.com to stay updated on atrasentan, zigakibart and the rest of the Chinook pipeline. For more information on the acquisition, see our press release at: https://www.novartis.com/news/media-releases/novartis-completes-acquisition-chinook-therapeutics See our community guidelines: https://go.novartis.social/3Slt0Up
- Website
-
http://www.chinooktx.com/
External link for Chinook Therapeutics, a Novartis Company
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Seattle, WA
- Type
- Public Company
- Founded
- 2019
- Specialties
- Rare Kidney Diseases, Nephrology, Drug Discovery, and Drug Development
Locations
-
Primary
Get directions
Seattle, WA 98102, US
-
Get directions
Vancouver, BC V5T 4T5, CA
Employees at Chinook Therapeutics, a Novartis Company
Updates
-
We are thrilled to announce that our Chief Scientific Officer, Andrew King, has been recognized as a 2023 PharmaVoice 100 honoree! This award is a testament to Andrew’s instrumental leadership, unrivaled knowledge and relentless drive intrinsic to a groundbreaking life sciences industry executive. With a focused and collaborative spirit, Andrew truly embodies Chinook’s core values and is deeply committed to revolutionizing the treatment landscape for individuals with rare, severe chronic kidney disease worldwide. Congratulations, Andrew! Learn more: https://bit.ly/3PH3yHs
-